Fda Ok of Sanofi’s type 2 diabetes med iGlarLixi pushed out to November

Fda Ok of Sanofi’s type 2 diabetes med iGlarLixi pushed out to November

This post was originally published on this site

At the FDA’s request, Sanofi submits additional information to the agency pertaining to the pen delivery device for its investigational once-daily fixed-dose combination of basal insulin glargine 100 Units/ml and GLP-1 receptor agonist lixisenatide, branded as iGlarLixi, for the treatment of adults with type 2 diabetes.